Population Pharmacokinetics and CD20 Binding Dynamics for Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL)

被引：0
|
作者：
Bender, Brendan C. [1 ]
Li, Chi-Chung [1 ]
Marchand, Mathilde [2 ]
Turner, David C. [1 ]
Li, Feifei [1 ]
Vadhavkar, Shweta [1 ]
Wang, Bei [1 ]
Deng, Rong [1 ]
Lu, James [1 ]
Jin, Jin [1 ]
Li, Chunze [1 ]
Yin, Shen [1 ]
Wei, Michael C. [1 ]
Chanu, Pascal [1 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Certara Inc, Marseille, France
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182086
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] A CD19/CD20-Directed Bispecific CAR-T Cell Therapy in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)
    Larson, Sarah M.
    Chen, Yvonne Y.
    Johnston, Jim
    Roy, Sylvain
    Patel, Pinakin
    Benjamin, Jonathan E.
    BLOOD, 2023, 142
  • [22] POPULATION PHARMACOKIN ETICS OF ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
    Padros, M. Bravo
    Conrado, D.
    Zhu, M.
    Srinivasan, K.
    Meng, X.
    Yan, H.
    Davis, J.
    Harnisch, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S69 - S69
  • [23] Response to Bridging Therapy (BT) before CAR-T Cell Infusion Predicts Outcomes for Relapsed/Refractory (R/R) Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)
    Khurana, Arushi
    Al Saleh, Abdullah S.
    Gandhi, Sangeetha
    Truong, Tuan A.
    Bennani, Nabila
    Paludo, Jonas
    Villasboas, Jose C.
    Johnston, Patrick B.
    Ansell, Stephen M.
    Lin, Yi
    BLOOD, 2020, 136
  • [24] Radiobiology of radioimmunotherapy: Targeting CD20 B-cell antigen in non-Hodgkin's lymphoma
    Hernandez, MC
    Knox, SJ
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (05): : 1274 - 1287
  • [25] Safety and efficacy of a novel anti-CD20/CD19 bispecific CAR T-cell therapy (C-CAR039) in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL).
    Liang, Aibin
    Zhou, Lili
    Li, Ping
    Yu, Wenjuan
    Yang, Min
    Xu, Yangyang
    Ye, Shiguang
    Zhu, Judy
    Huang, Jiaqi
    Zhang, Yan
    Li, Lanfang
    Zhao, Jing
    Li, Jing
    Zheng, Chengxiao
    Zhu, Kevin
    Lan, Liping
    Zhang, Huilai
    Zhou, Daobin
    Yao, Yihong
    Jin, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] Promising Tolerability and Efficacy Results from Dose-Escalation in an Ongoing Phase Ib/II Study of Mosunetuzumab with Polatuzumab Vedotin (Pola) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
    Budde, Elizabeth
    Ghosh, Nilanjan
    Chavez, Julio
    Lossos, Izidore S.
    Mehta, Amitkumar
    Dorritie, Kathleen
    Kamdar, Manali
    Negricea, Raluca
    Song Pham
    Hristopoulos, Maria
    Huw, Ling-Yuh
    O'Hear, Carol
    Oki, Yasuhiro
    To, Iris
    Diefenbach, Catherine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S393 - S394
  • [27] Population Pharmacokinetics of Epcoritamab Following Subcutaneous Administration in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
    Li, Tommy
    Gibiansky, Leonid
    Parikh, Apurvasena
    van der Linden, Marcel
    Sanghavi, Kinjal
    Putnins, Matthew
    Sacchi, Mariana
    Feng, Huaibao
    Ahmadi, Tahamtan
    Gupta, Manish
    Xu, Steven
    CLINICAL PHARMACOKINETICS, 2025, 64 (01) : 127 - 141
  • [28] Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma
    Tsai, Ping-Chiao
    Hernandez-Ilizaliturri, Francisco J.
    Bangia, Naveen
    Olejniczak, Scott H.
    Czuczman, Myron S.
    CLINICAL CANCER RESEARCH, 2012, 18 (04) : 1039 - 1050
  • [29] A Phase 2 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody (Ab), in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
    Topp, Max S.
    Duell, Johannes
    Li, Jingjin
    Jankovic, Vladimir
    Lowy, Israel
    Sternberg, David
    Adriaens, Lieve
    Peterman, Mary
    Ambati, Srikanth R.
    Bannerji, Rajat
    BLOOD, 2019, 134
  • [30] Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with Relapsed/Refractory (R/R) B-cell non-Hodgkin Lymphomas (B-NHL): updated results from a Phase I/II study
    von Tresckow, B.
    Budde, L. E.
    Bartlett, N. L.
    Giri, P.
    Schuster, S. J.
    Assouline, S.
    Yoon, S. S.
    Fay, K.
    Matasar, M.
    Gutierrez, N. C.
    Marlton, P.
    Dreyling, M.
    Yoon, D. H.
    Hess, G.
    Radford, J.
    Wiebking, V.
    Yin, S.
    Cybulski, E.
    Turner, D. C.
    Huang, H.
    Zhou, M.
    Penuel, E.
    Wei, M. C.
    Sehn, L. H.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 206 - 207
12345